Inotiv, Inc.

Is Inotiv, Inc. overvalued or undervalued?

As of February 10, 2022, Inotiv, Inc. is considered risky and overvalued with poor financial metrics and significant underperformance, reflected in a year-to-date return of -64.98% and a 3-year return of -93.17%, compared to the S&P 500's gains.

As of 10 February 2022, the valuation grade for Inotiv, Inc. has moved from fair to risky, indicating a deterioration in its financial standing. The company is currently overvalued, as evidenced by its Price to Book Value of 0.59, an EV to Sales ratio of 1.00, and a troubling ROE of -57.12%. In comparison, FONAR Corp., which is rated fair, has a P/E ratio of 8.9956 and an EV to EBITDA of 2.7084, highlighting the significant disparity in valuation metrics among peers.<BR><BR>Inotiv's performance has been notably poor, with a year-to-date return of -64.98% compared to the S&P 500's gain of 12.22%, and a staggering 3-year return of -93.17% against the S&P 500's 70.41%. This stark contrast reinforces the notion that Inotiv is not only struggling in terms of valuation but also underperforming significantly relative to broader market benchmarks.

Is Inotiv, Inc. technically bullish or bearish?

As of September 8, 2025, Inotiv, Inc. is in a bearish trend, indicated by negative MACD, moving averages, and Bollinger Bands, with a year-to-date return of -64.98% compared to the S&P 500's 12.22%.

As of 8 September 2025, the technical trend for Inotiv, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish signal from Bollinger Bands on both weekly and monthly timeframes. Additionally, the Dow Theory indicates a mildly bearish stance on the weekly and monthly levels. <BR><BR>In terms of performance, Inotiv has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -64.98% versus the S&P 500's 12.22%, and a 3-year return of -93.17% compared to the S&P 500's 70.41%.

How big is Inotiv, Inc.?

As of Jun 18, Inotiv, Inc. has a market capitalization of 70.42 million, with net sales of 480.41 million and a net profit of -87.48 million over the latest four quarters. The company reported shareholder's funds of 170.50 million and total assets of 841.43 million as of Sep 24.

Market Cap: As of Jun 18, Inotiv, Inc. has a market capitalization of 70.42 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Inotiv, Inc. reported net sales of 480.41 million and a net profit of -87.48 million.<BR><BR>Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 170.50 million and total assets of 841.43 million.

What does Inotiv, Inc. do?

Inotiv, Inc. is an international contract research company specializing in drug discovery and development services, with a market capitalization of $70.42 million. As of March 2025, it reported net sales of $124 million and a net loss of $15 million.

Overview:<BR>Inotiv, Inc. is an international contract research company providing drug discovery and development services and analytical instruments, operating in the Miscellaneous industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 124 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 70.42 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.47 <BR>Return on Equity: -57.12% <BR>Price to Book: 0.45<BR><BR>Contact Details:<BR>Address: 2701 Kent Ave, WEST LAFAYETTE IN: 47906-1350 <BR>Tel: 1 317 4634527 <BR>Fax: 1 765 4971102 <BR>Website: http://www.basinc.com/

Should I buy, sell or hold Inotiv, Inc.?

Who are in the management team of Inotiv, Inc.?

As of March 2022, the management team of Inotiv, Inc. includes Dr. Gregory Davis (Interim Chairman), Mr. Robert Leasure (President and CEO), Dr. John Sagartz (Chief Strategy Officer), and three Independent Directors: Dr. Richard Johnson, Mr. R. Matthew Neff, and Ms. Wendy Perrow. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Inotiv, Inc. includes the following individuals:<BR><BR>- Dr. Gregory Davis, who serves as the Interim Chairman of the Board.<BR>- Mr. Robert Leasure, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. John Sagartz, who holds the position of Chief Strategy Officer and is also a Director.<BR>- Dr. Richard Johnson, who is an Independent Director.<BR>- Mr. R. Matthew Neff, who is another Independent Director.<BR>- Ms. Wendy Perrow, who is also an Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and operations of the company.